Zoladex
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $171,669 | 2,607 | 1,815 |
| 2023 | $150,435 | 2,249 | 1,642 |
| 2022 | $38,894 | 271 | 207 |
| 2021 | $3,370 | 101 | 77 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $185,849 | 104 | 51.0% |
| Food and Beverage | $124,041 | 4,954 | 34.0% |
| Travel and Lodging | $26,700 | 107 | 7.3% |
| Space rental or facility fees (teaching hospital only) | $18,350 | 8 | 5.0% |
| Unspecified | $5,568 | 45 | 1.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,388 | 5 | 0.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,260 | 2 | 0.3% |
| Education | $213.50 | 3 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma: Big Ten Cancer Research Consortium | TerSera Therapeutics LLC | $5,568 | 0 |
Top Doctors Receiving Payments for Zoladex — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Nuclear Radiology | Guilford, CT | $2,795 | 7 |
| , MD | Surgery | Windemere, FL | $2,619 | 1 |
| , MD | Medical Oncology | Stamford, CT | $2,513 | 2 |
| , MD | Medical Oncology | Oak Park, IL | $2,377 | 1 |
| , MD MPH | Internal Medicine | Rochester, MN | $2,271 | 1 |
| , MD | Internal Medicine | Sugar Land, TX | $2,254 | 1 |
| , M.D | Internal Medicine | Boston, MA | $2,238 | 4 |
| , M.D | Internal Medicine | New York, NY | $2,207 | 3 |
| , MD | Internal Medicine | Mars, PA | $2,095 | 2 |
| Margarite Matossian | Internal Medicine | Riverside, IL | $2,095 | 2 |
| Hannah Linden | Medical Oncology | Seattle, WA | $2,088 | 1 |
| , MD | Internal Medicine | Brookline, MA | $2,085 | 1 |
| Erica Stringer-Reasor | Hematology & Oncology | Hoover, AL | $2,085 | 1 |
| , M.D | Medical Oncology | Boston, MA | $2,000 | 1 |
| , MD, PHD | Radiation Oncology | New York, NY | $1,850 | 2 |
| , M.D | Internal Medicine | New York, NY | $1,617 | 3 |
| , FNP-C | Family | Houston, TX | $1,563 | 2 |
| , M.D., D.PHIL | Medical Oncology | Woodbridge, CT | $1,440 | 3 |
| , MD | Hematology & Oncology | Rochester, MN | $1,182 | 3 |
| , MD | Medical Oncology | Sherman Oaks, CA | $1,182 | 3 |
| , M.D | Internal Medicine | Tucson, AZ | $1,182 | 3 |
| , MD | Specialist | Pittsburgh, PA | $1,182 | 3 |
| , MD | Internal Medicine | Indianapolis, IN | $1,182 | 3 |
| , M.D | Internal Medicine | Scarsdale, NY | $1,182 | 3 |
| , M.D | Medical Oncology | Brookline, MA | $1,137 | 6 |
Manufacturing Companies
- TerSera Therapeutics LLC $364,369
Product Information
- Type Drug
- Total Payments $364,369
- Total Doctors 2,985
- Transactions 5,228
About Zoladex
Zoladex is a drug associated with $364,369 in payments to 2,985 healthcare providers, recorded across 5,228 transactions in the CMS Open Payments database. The primary manufacturer is TerSera Therapeutics LLC.
Payment data is available from 2021 to 2024. In 2024, $171,669 was paid across 2,607 transactions to 1,815 doctors.
The most common payment nature for Zoladex is "Consulting Fee" ($185,849, 51.0% of total).
Zoladex is associated with 1 research study, including "Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma: Big Ten Cancer Research Consortium" ($5,568).